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suggestive evidence that circular EBV-D:\A mole-
cules are replicated by cellular D:\A polymerases. In 
vitro EBV-transformed cell cultures are known to be 
resistant to acvclovir. 13.16.24 This obsen'ation and our 
clinical experience suggest a need to develop anti-
EBV agents directed against viral targets other than 
the a~A polymerase. 
In conclusion, we have developed a simple gel 
technique that may be useful in the discrimination 
of permissive from nonpermissive EB\'-induced hm-
phoproliferative disorders. Such studies may help 
physicians to choose between antiviral chemotherapy 
and traditional cytotoxic chemotherapy in the treat-
ment of such disorders. 
We are indebted to Christine "·right. ~lKp .. and Barbara Racklin. 
B.A., for excellent technical assistance and to ~frsK Kathv Beaure-
gard for assistance in preparing the manuscript. 
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ISOHEMAGGLUTININS OF GRAFf ORIGIN 
AFfER ABO-UNMATCHED LIVER 
TRANSPLANTATION 
GLENN RAMSEY, M,D" JACOB NUSBACHER, M.D., 
THOMAS E. STARZL, M,D., PH.D., 
AND GWENN D. LINDSAY, B.A. 
T HE increasing success of liver transplantation in 
recent years has provided an experimental model 
to study and document the hepatic synthesis of many 
plasma proteins. l•5 The normal hepatobiliary tract 
has not been regarded as a major source of anti-
body,6,7 aside from the enteric IgA secreted from plas-
ma into the biliary tree.s Liver transplantation affords 
the opportunity to study the production of antibody to 
red cells. Recipient ABO incompatibility to the donor 
(a mismatched transplant, e.g., a group A liver trans-
planted into a group B recipient), although not ab-
solutely contraindicated in liver transplantation, is 
avoided when possible. However, ABO-unmatched 
transplants (defined as a group 0 liver transplanted 
into a non-group 0 recipient or a group A or B liver to 
an AB recipient) are used frequently. We report the 
short-term occurrence of anti-recipient ABO antibody 
after eight unmatched transplants. In five cases there 
was evidence of hemolysis. :'-10 such antibodies have 
been seen in over 180 ABO-matched transplants at 
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our center. These antibodies were most probably pro-
duced by donor lymphocytes transplanted in or with 
the livers. 
METHODS 
Serologic studies were performed according to standard meth-
OOs.9 Serum isohemagglutinins were tested without intubation, after 
37°C incubation for 30 minutes, and with broad-spectrum antiglob-
ulin reagents. 
Six patients with ABO-unmatched liver transplants and con-
firmed anti-recipient antibody production were studied prospective-
ly. Blood samples were drawn at least weekly for direct and indirect 
antiglobulin testing, crossmatching, and elutions. The hematocrit, 
serum bilirubin, clinical status, and transfusions were closely moni-
tored. Two other confirmed cases (in Patients 5 and 7) were found 
on review of all ABO-unf!latched liver transplantations performed 
at our center. Confirmed cases of isohemagglutinin production were 
defined as those in which passive transfer of antibody could be ruled 
out - i.e., either no unmatched plasma-containing blood products 
were given at surgery (five cases) or, if they were, immediate postop-
erative specimens were negative for antibody (Patients lA, I B, and 
6) - and there was serologic or clinical confirmation of the anti-
body's presence by repeat testing or signs of hemolysis. Cases were 
designated as possible if the antibody was first detected after the 
second postoperative day but the above criteria were not met 
in full. 
Liver transplantation was performed according to established 
techniques, including cyclosporine immunosuppression. 10,1 1 Little 
or no plasma was transferred in the grafts because the livers were 
copiously perfused with preservative solution and then, just before 
anastomosis, with saline. 12 Our transfusion practices have been de-
scribed elsewhere. 13 
REsULTS 
One hundred seventy-one patients underwent a to-
tal of 225 orthotopic liver transplantations at the U ni-
versity of Pittsburgh from February 26, 1981, to Janu-
ary 20, 1984. Unmatched livers were transplanted in 
40 instances (18 per cent). In 33 of these, a non-group 
o patient (16 group A, 15 group B, and 2 group AB 
patients) received a group 0 liver. The other seven 
unmatched transplants were in group AB patients 
who received group A (five) or group B (two) livers. 
Table I summarizes the prevalence of anti-recipient 
ABO antibodies in the 40 unmatched transplants. 
Such antibodies were demonstrated in 8 of29 evalua-
ble cases (28 per cent). In addition, anti-recipient 
ABO antibodies were possibly present in five other 
transplants (17 per cent). In 13 cases no antibody was 
seen in specimens tested during 7 to 21 days after 
surgery. In three instances, antibody was detected one 
day after unmatched blood components had been giv-
en at surgery but all subsequent specimens were nega-
tive; these findings were attributed to the transient 
presence of passively acquired antibody. Eleven pa-
tients were not evaluable because of early death (four), 
the preoperative presence of anti-AI in group A2 pa-
tients (two), or the absence of blood-bank specimens 
during the first 7 to 21 days (five). 
Table 2 shows the clinical and serologic characteris-
tics of the eight ABO-unmatched patients in whom the 
presence of anti-recipient ABO antibody was con-
firmed. When studied with monospecific antiglobulin 
reagents, all patients had complement and five had 
IgG on their red cells. When studied with polyspecific 
Table 1, Prevalence of Anti-Recipient ABO Antibody in 40 Con-
secutive ABO-Unmatched Uver Transplants. 
BLOOD GIOUPS OF 
PUv ALIlNCE OF ANTIBoDY DoNOI-IUaPlENT TOTAL 
O-Non-O AorB-AB 
flO. of rtcipiePIIJ 
Antibody formation 7 8 
Possible antibody 5 0 S 
No antibody 12 13 
No antibody except passive 2 I 3 
Not evaluable 7 4 1\ 
Total no. of transplants 33 7 40 
antiglobulin reagents, freeze-thawing or heat-induced 
eluates from the patients' red cells gave I + to 3+ 
reactions with other red cells of the same ABO group. 
In three of the transplants from group 0 donors, anti-
A,B was present in eluates in addition to anti-A or 
anti-B alone in the serum. Reactions of the patients' 
serum samples against appropriate red cells ranged 
from weak to 2+ by indirect antiglobulin testing. The 
reaction strength did not correlate with the degree of 
hemolysis. Serum samples from two patients (lA and 
3) were treated with dithiothreitol to inactivate IgM; 
both had residual activity when tested with antiglobu-
lin reagents, indicating the presence of IgG antibody. 
No other irregular red-cell antibodies were detected 
with group 0 screening cells, except for one instance 
of anti-Kell in serum. 
There was evidence of hemolysis in five cases. The 
changes in hematocrit shown in Table 2 occurred over 
two to three days, well after the period of peri operative 
transfusion requirements (see below), and were not 
associated with hemorrhage. Concurrent increases in 
total and indirect serum bilirubin were also noted. 
Rejection could not be ruled out as a factor contribut-
ing to the elevation in total bilirubin levels, but it is not 
known to cause sudden anemia. 
Figure I shows the period when the anti-recipient 
ABO antibodies were present. The antibodies were 
first detected 8 to 16 days after transplantation and 
were last detected at II to 41 days. Hemolysis, when it 
occurred, began 5 to 8 days after surgery and lasted for 
7 to 19 days. In Figure I, the final red-cell transfusion 
of the episode is used to indicate the end of hemolysis. 
In two cases complement was still present on the red 
cells for prolonged periods after the ABO antibody 
was undetectable. 
Five of these eight grafts have survived for 5 to 16 
months; repeat transplants were necessary after her-
pesvirus and cytomegalovirus hepatitis in Patients IA 
and 3 and after rejection in Patient 7. All patients 
except Patient 3 have survived. 
DISCUSSION 
I n each of the eight cases reported here, circulating 
and red-cell-bound isohemagglutinins to the patient's 
own A or B antigen were detected 8 to 16 days after 
transplantation of a liver from an ABO-unmatched 
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Table 2. Patients in Whom Anti-Recipient ABO Antibody Was Detected, 
PATIENT 
No. 
4 
5 
6 
7 
AGE/SEX 
261M 
191F 
281M 
271M 
21M 
521M 
51F 
DlAGNOSIS 
Wilson's disease 
Non·A.Ron·B hep-
atitis 
Sclerosing cholangitis 
Hepatitis B 
(I,' Antitrypsin 
deficiency 
Alcoholic cirrhosis 
ai-AntItrypsin 
deficiency 
ABO G.ocPS 
DONOR PATIENT 
0 B 
0 B 
0 B 
0 B 
0 B 
0 A, 
0 A, § 
A AB 
'TIle direct antiglobulin test IS spec!flc for IgG or complement Ie). 
ANTIBODY IN 
ELUATE 
To B 
To B:A.B 
To B 
To B:A.B 
To B 
To A, 
To A:A.B 
To B ~ 
DIRECT ANTI- INDIRECT ANn· CKANGE IN 
GLOBULIN TEST • GLOBULIN TEST t HEMATOCRIT 
19O C IS 37'C AGT 
+ 1+ W W From 42-24% 
+ W N W None 
+ + N 1+ 1+ From 41-28% 
+ + 4+ 3+ 2+ From 38-23% 
+ + N W w Gl hemorrhage 
+ N N W From 44·20% 
+ + N N W None 
+ + 1+ 2+ 1+ From 42·12% 
tFor the Indirect antiglobulin itS! with IInmedialt spiMing (IS). 37'C. and antiglobulin testing (AGT). W denOles weal< and N negative. 
UA and I B refer to the second and third transplantatrons in Paucnt l. Group 0 red cells were given al the third U'allsplantauon. 
fA) tyPIRS was performed on rcticulocytc:-enriched red cells 48 days afler surllcry. 
~Aati-hell was aho prescnt In serum. bUI not in a red-cell eluate. 
donor. Evidence of hemolysis was present in five of the 
seven patients. The antibodies persisted for 2 to 41/2 
weeks. Passive transfer of antibody from the liver itself 
or from transfusions was ruled out. The findings in 
Patient 5, in theory, may represent hemolytic anti-AI 
alloimmunization in a group A2 patient, but this is 
extremely rare_ 14 
We conclude that these antibodies most probably 
originate from B lymphocytes that are transplanted in 
or with the donor liver and then respond to the recipi-
ent's ABO antigens in a type of graft-versus-host reac-
tion. A large number of lymphocytes may accompany 
Gase 
lA 
ANTI-RECIPIENT ABO ANTIBODIES 
2 c' -+ 80+ 
4 
5 
6 ~ + Anlibody 
o Hemolysis 
o NeQclive 
Results 
7 
o 10 20 30 40 50 60 
Days of ler Tr on splan I 
Figure 1 . Presence of Anti-Recipient ABO Antibodies and Hemol-
ysis after ABO-Unmatched Liver Transplantation. 
C' Indicates the persistence of complement on red cells in the 
final samples obtained at 133 and 80 days. 
the liver in the lymphatics l5•16 and lymph nodes_ 17 
The 8-to-16-day latency period and the frequently ob-
served IgG component of the antibodies are consistent 
with a secondary immune response from previously 
primed donor B lymphocytes. In addition, cyclospo-
rine does not blunt secondary immune responses as 
much as primary ones. 18•19 Proof that these antibodies 
are of donor origin could be obtained by immunoglo-
bin allotyping, but in our patients this is often pre-
cluded by plasma transfusions before and at surgery. 
Production of anti-recipient red-cell antibodies has 
also been associated with spleen,20.21 kidney,22.28 and 
lung29 transplantation. All except one report25 in-
volved ABO antibodies. ABO-unmatched splenic 
grafts have induced severe hemolysis. Patients with 
renal grafts, like our patients, have had short-lived, 
usually hemolytic antibodies appearing one to two 
weeks after transplantation. Designation of these anti-
bodies as "autoantibodies" 22.24-29 tends to obscure 
their true pathogenesis. 
Unless the supply of donor organs increases to allow 
uniform ABO matching, ABO-unmatched liver trans-
plantation is likely to continue. To date, 20 per cent of 
our group A recipients, 56 per cent of our group B 
recipients, and 90 per cent of our group AB recipients 
have received ABO-unmatched livers. Our current 
transfusion policy in such cases is to use recipient-type 
blood components initially and to monitor the patients 
for anti-recipient ABO antibodies. If they appear, do-
nor-type packed red cells are given when needed 
throughout the period when the antibody is present. 
During our prospective study, these red cells were 
washed to remove blood-donor antibodies, but the 
small amount of antibody in the plasma of packed red 
cells is unlikely to be harmful to the recipient. Plasma, 
if needed, should be of the recipient'S ABO type; the 
soluble ABO antigens therein may neutralize some of 
the ABO alloantibody.14 
We are indebted to David Salamon for valuabk discussions. to 
Linda Israel and the blood-bank statrfor technical expertise. to Paul 
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Chervenick, M.D., and Jessica H. Lewis, M.D., for helpful com-
ments, and to Linda Lippert and Ruby Love for help in preparing 
the man uscript. 
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CASE 44-1984 
PRESENTATION OF CASE 
A 15-year-old girl was admitted to the hospi tal be-
cause of a question of chronic active hepatitis. 
She was well until 11/2 years earlier, when she began 
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elbows and knees. One year before admission a physi-
cian made a diagnosis of infectious mononucleosis and 
prescribed prednisone, without improvement. Eight 
months before entry orthodontic braces were fitted, 
and she began to notice bleeding gums. Five months 
before admission anemia was found. A physician 
made a diagnosis of mycoplasma infection, but the 
administration of iron and an antibiotic had no effect. 
The resul\s of tests of liver function were reported to 
be normal. 
One month before entry she complained of "sinus 
headaches." Laboratory studies revealed abnormali-
ties in tests of liver function. and she was admitted to 
another hospital. Examination revealed scleral icterus, 
lymphadenopathy, and hepatosplenomegaly. :"ieuro-
logic examination was negat.ve; no Kayser-Fleischer 
rings were observed on slit-lamp examination. The 
hematocrit was 33 per cent. The prothrombin time 
was 17.5 seconds, with a control of 12 seconds. The 
bilirubin was 2.2 mg per 100 ml (38 I-Lmol per liter). 
The aspartate aminotransferase (SGOT) was 591 U 
per milliliter (4.73I-Lmol· sec-I per liter), the glutamic 
pyruvic transaminase (SGPT) :257 V, and the alkaline 
phosphatase 4- 7 U. The serum copper was 120 I-Lg per 
100 ml (191-Lmol per liter) (normal, 100 to 200 I-Lg [20 
to 30 I-LmoIJ). The ceruloplasmin was 0.17 g per liter 
(normal, greater than 0.23 g). In a 24-hour specimen 
